Replies to post #223288 on Biotech Values

[biotech_researcher]

AUPH- On the call now. Not a flop at all as the market will show today.. They just picked the wrong endpoint for the trial..

[northern vortex]

Ron – regarding AUPH’s recent DES results – I suggest that one go directly to the study results released by AUPH rather than rely on the loaded spin supplied by AF in STATNEWS; which appears to be endorsed by you. I wouldn’t call results demonstrating statistically greater efficacy “a flop”. Furthermore, I couldn’t find any difference in tolerability between treatments in the AUPH NR, as stated in the STATNEWS article.

https://ir.auriniapharma.com/press-releases/detail/131/aurinia-announces-voclosporin-ophthalmic-solution